Stock to buy: Avendus initiates coverage on Dr Agarwal’s Health Care with 'buy' rating; sees 18.3% upside

The healthcare sector, particularly specialized segments like eye care, is experiencing growth due to increasing demand and improving healthcare infrastructure. Analyst coverage can significantly influence stock performance.

• •Avendus Spark Institutional Equities initiated coverage on Dr. Agarwal’s Health Care.
• •Given a 'buy' rating with a target price of ₹495.
• •Anticipates strong growth driven by acquisitions and surgical revenues.
• •Risk flag: Execution risk of acquisitions
• •Risk flag: Competition in the eye care market